Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor–like factor 2 (CRLF2), and other tumors with constitu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Weigert, Oliver, Lane, Andrew A., Bird, Liat, Kopp, Nadja, Chapuy, Bjoern, van Bodegom, Diederik, Toms, Angela V., Marubayashi, Sachie, Christie, Amanda L., McKeown, Michael, Paranal, Ronald M., Bradner, James E., Yoda, Akinori, Gaul, Christoph, Vangrevelinghe, Eric, Romanet, Vincent, Murakami, Masato, Tiedt, Ralph, Ebel, Nicolas, Evrot, Emeline, De Pover, Alain, Régnier, Catherine H., Erdmann, Dirk, Hofmann, Francesco, Eck, Michael J., Sallan, Stephen E., Levine, Ross L., Kung, Andrew L., Baffert, Fabienne, Radimerski, Thomas, Weinstock, David M.
Format: Artigo
Jezik:Inglês
Izdano: The Rockefeller University Press 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3280877/
https://ncbi.nlm.nih.gov/pubmed/22271575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111694
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki